Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

413
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
413
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

240
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
240

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Serum Metabolomic Signatures Related to Integrase Strand Transfer Inhibitors-Associated Weight Gain in Women with HIV Enrolled in the MACS/WIHS Combined Cohort Study.

The Journal of infectious diseases·2026
Same author

Readmissions following urban hospital closure.

Journal of hospital medicine·2026
Same author

Knowledge Graph Augmented Large Language Models for Disease Prediction.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same author

Social Partner Effects on Type 2 Diabetes Prevention, Management, and Spillover Health Outcomes: Single-Arm Pre-Post Pilot Intervention.

JMIR formative research·2026
Same author

Comparing Approaches for Deriving Diabetes Care Cascades to Inform Policy: A Cross-sectional Analysis Using National Data From 88 Countries.

Diabetes care·2026
Same author

Subtypes of Type 2 Diabetes and Prediabetes: Mortality and Excess Life Lost in South Asians.

Diabetes care·2026
Same journal

Post-myomectomy age-specific ongoing pregnancy rates in women ≥37 years old: a retrospective non-comparative study.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2026
Same journal

Retraction Statement: Knowledge, attitude, and practice of obstetricians towards vaginal birth after caesarean in Egypt.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2026
Same journal

Beyond an incidental finding: Reframing persistent left superior vena cava as a marker of comprehensive foetal cardiovascular assessment.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2026
Same journal

Including support people in gestational diabetes mellitus education: Understanding providers' perspectives.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2026
Same journal

Sociodemographic factors shaping knowledge-attitude-behaviour pathways in postpartum fall prevention.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2026
Same journal

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2026
See all related articles

Related Experiment Video

Updated: Jan 4, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

10.0K

Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a

Ayman H Shaamash1, Mohammed K Ali1, Khalid M Attyia1

  • 1Department of Obstetrics and Gynaecology, Faculty of Medicine, Woman's Health Hospital, Assiut University, Assiut, Egypt.

Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology
|November 1, 2019
PubMed
Summary
This summary is machine-generated.

17α-hydroxyprogesterone caproate (17α-OHP-C) significantly reduced preterm delivery in women with placenta previa. This treatment also decreased bleeding episodes and improved neonatal outcomes, supporting its use as a beneficial tocolytic agent.

Keywords:
17α-hydroxyprogesterone caproateplacenta praevia; preterm delivery

More Related Videos

Mouse In Vivo Placental Targeted CRISPR Manipulation
07:39

Mouse In Vivo Placental Targeted CRISPR Manipulation

Published on: April 14, 2023

3.4K
Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

2.1K

Related Experiment Videos

Last Updated: Jan 4, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

10.0K
Mouse In Vivo Placental Targeted CRISPR Manipulation
07:39

Mouse In Vivo Placental Targeted CRISPR Manipulation

Published on: April 14, 2023

3.4K
Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

2.1K

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Pharmacology

Background:

  • Placenta previa is a significant risk factor for preterm labor and associated neonatal complications.
  • Rising cesarean section rates have correlated with an increased incidence of placenta previa.
  • Effective and safe tocolytic agents for managing placenta previa remain to be fully established.

Purpose of the Study:

  • To evaluate the efficacy of 17α-hydroxyprogesterone caproate (17α-OHP-C) in reducing preterm delivery (PTD) among women diagnosed with placenta previa.
  • To assess the impact of 17α-OHP-C on bleeding attacks, gestational age at birth, and neonatal birth weight in this patient population.

Main Methods:

  • A randomized controlled trial involving 114 women with placenta previa between 24 and 28 weeks of gestation.
  • Participants were assigned to receive either weekly intramuscular injections of 17α-OHP-C (250 mg) until 37 weeks or no 17α-OHP-C treatment.
  • Outcomes measured included rates of PTD, gestational age, number of bleeding attacks, and birth weight.

Main Results:

  • The 17α-OHP-C group showed a significantly lower percentage of preterm delivery (approximately 37%) compared to the control group (63.5%, p=0.004).
  • Mean gestational age was significantly longer in the 17α-OHP-C group (36.7 ± 0.7 weeks vs. 34.9 ± 1.2 weeks, p<0.000).
  • Patients receiving 17α-OHP-C experienced fewer bleeding attacks and had higher mean birth weights (2841 ± 159 g vs. 2561 ± 168 g, p<0.000).

Conclusions:

  • Maintenance tocolysis with intramuscular 17α-OHP-C is beneficial for women with placenta previa.
  • The treatment effectively reduces bleeding episodes, the incidence of preterm delivery, and neonatal intensive care unit admissions.
  • 17α-OHP-C demonstrates potential as an effective, safe, and well-tolerated tocolytic agent for placenta previa, warranting further large-scale investigation.